Deciphera's Stomach Cancer Treatment Shows Clinical Benefit In Subgroup Of Patients

Deciphera Pharmaceuticals Inc DCPH announced an exploratory analysis of data from the INTRIGUE Phase 3 study of Qinlock using circulating tumor DNA (ctDNA).
The data comes from a subgroup of patients with gastrointestinal stromal tumors (GIST) previously treated with imatinib who harbor mutations in KIT exon 11 and 17/18 only.
Patients with mutations in KIT exon 11 and exon 17/18 only had substantially improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) with Qinlock versus Pfizer Inc's PFE Sutent (sunitinib).
Related: Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer.
The median progression-free survival for Qinlock of 14.2 months versus sunitinib of 1.5 months.
The objective response rate of 44.4% for Qinlock versus 0% for sunitinib.
The median overall survival for Qinlock was not estimable versus 17.5 months for sunitinib.
The company plans to initiate the INSIGHT pivotal Phase 3 study of Qinlock versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18 only in 2H of 2023.
Separately, Deciphera posted interim Q4 sales of approximately $36 million and FY22 revenue of approximately $134 million.
Qinlock net product revenue is estimated to be approximately $33 million.
A cash balance of $339 million is expected to provide a runway into 2025.
Price Action: DCPH shares are up 2.82% at $16.39 during the premarket session on the last check Wednesday.